...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis.
【24h】

Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis.

机译：糠酸莫米他松鼻喷雾剂对变应性鼻炎的个体眼部症状的影响：一项荟萃分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Intranasal corticosteroids (INSs) are a mainstay of treatment of allergic rhinitis (AR) nasal symptoms. The INS mometasone furoate nasal spray (MFNS) has well-documented efficacy and safety for the treatment and prophylaxis of nasal symptoms of seasonal AR (SAR) and for the treatment of nasal symptoms of perennial AR (PAR). Increasing interest has focused on whether INSs, including MFNS, may have beneficial effects on the ocular symptoms frequently associated with AR. METHODS: We performed a meta-analysis of 10 randomized, placebo-controlled trials of the efficacy of MFNS 200 mcg daily in relieving ocular allergy symptoms, including itching/burning, redness, and tearing/watering in both SAR and PAR. Four PAR studies and six SAR studies are included in the analysis. A fixed-effect inverse variance model was used to calculate weighted mean differences, 95% confidence intervals (CIs) for each comparison, and a combined overall treatment effect (Z) with P-value. RESULTS: In both analyses of SAR and PAR studies, including 3132 patients, all individual ocular symptoms were reduced in patients treated with MFNS. Overall treatment effect was significant for all three individual ocular symptoms in the SAR studies (Z = 9.18 for tearing, Z = 10.15 for itching, and Z = 8.88 for redness; P < 0.00001 for all) and in the PAR studies (Z = 5.94, P < 0.00001 for tearing; Z = 2.43, P = 0.02 for itching; and Z = 2.42, P = 0.02 for redness). CONCLUSIONS: Our findings add to the growing body of literature supporting the positive class effect of INSs, including MFNS, on ocular symptoms associated with SAR and PAR.
机译：背景：鼻内皮质类固醇（INS）是治疗过敏性鼻炎（AR）鼻部症状的主要手段。 INS糠酸莫米他松鼻喷雾剂（MFNS）在治疗和预防季节性AR（SAR）的鼻部症状以及常年性AR（PAR）的鼻部症状方面具有广泛的疗效和安全性。越来越多的关注集中在包括MFNS在内的INS是否可能对经常与AR相关的眼部症状产生有益影响。方法：我们进行了10项随机，安慰剂对照试验的荟萃分析，这些试验涉及每天200 mcg MFNS缓解SAR和PAR的眼部过敏症状，包括瘙痒/烧伤，发红和流泪/浇水。分析中包括四个PAR研究和六个SAR研究。使用固定效应逆方差模型来计算加权平均差异，每个比较的95％置信区间（CIs）以及结合P值的总体治疗效果（Z）。结果：在SAR和PAR研究的分析中，包括3132例患者，用MFNS治疗的患者的所有个体眼部症状均得到减轻。在SAR研究中，所有三种单独的眼部症状的总体治疗效果都很显着（对于撕裂而言，Z = 9.18，对于瘙痒，Z = 10.15，对于发红，Z = 8.88;对于所有情况，P <0.00001），在PAR研究中（Z = 5.94） ，对于撕裂，P <0.00001;对于瘙痒，Z = 2.43，P = 0.02;对于发红，Z = 2.42，P = 0.02）。结论：我们的发现增加了支持INS（包括MFNS）对与SAR和PAR相关的眼部症状的积极分类作用的文献，这一文献不断增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号